Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Dollar Holds Firm Ahead of Global Central Bank Decisions as Yen, Sterling and Euro React 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
BoE Set to Cut Rates as UK Inflation Slows, but Further Easing Likely Limited 
Oil Prices Steady in Asia but Headed for Weekly Loss on Supply Glut Concerns 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Singapore Growth Outlook Brightens for 2025 as Economists Flag AI and Geopolitical Risks 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Oil Prices Climb on Venezuela Blockade, Russia Sanctions Fears, and Supply Risks 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
South Korea Warns Weak Won Could Push Inflation Higher in 2025 
Precious Metals Rally as Silver and Platinum Outperform on Rate Cut Bets 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Japan Inflation Holds Firm in November as BOJ Nears Key Rate Hike Decision 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
CHA Healthcare Co., a South Korean medical hospital operator, announced on Monday, June 28, that it has secured management rights to Fertility Specialists of Western Australia (FSWA) via an acquisition deal.
The FSWA is a major fertility center located in Western Australia and it was through City Fertility National Network, an Australian in-vitro fertilization (IVF) service group, that CHA Healthcare was able to make the deal. The CFNN is a subsidiary of the Korean healthcare company.
As per The Korea Economic Daily, the FSWA is running two fertility centers in Perth, and centers carry out more than 1,200 IVF treatments per year. This number is said to make up 30% of all the IVF treatments done in the region.
With its acquisition of the Australian fertility center, CHA Healthcare Co. is now aiming to conduct over 10,000 in-vitro fertilization treatments annually by the year 2026. The deal also marks the Korean medical operator's expansion in the Australian infertility treatment market.
The company first entered Australia in 2018 when it purchased the Queensland-based City Fertility, which has seven local fertility facilities. With the addition of FSWA in its acquisition portfolio, CHA Healthcare has now expanded the number of its fertility centers to 18 across AU and is targeting states that have a high percentage of women of childbearing age. Such locations include Sydney, Brisbane, and Melbourne.
"CHA Healthcare has built a solid foundation for international medical care in Australia," Cho Seong Soo, CHA Healthcare's chief executive officer, said in a statement. "We aim to expand the global network in Southeast Asian countries such as Vietnam and Indonesia."
Korea Joongang Daily reported that the deal is in line with CHA Healthcare's move to further boost its presence in the fertility treatment market in Australia. Meanwhile, the Korean healthcare firm was launched in 2013 as a subsidiary of CHA Biotech Co. Ltd, which is the leading stem cell therapeutics developer in the country. Aside from Australia and Korea, the company is also running 81 general acute care medical hospitals and IVF clinics in various countries including Singapore, the U.S., and Japan.
